- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prevention of lower respiratory tract disease caused by respiratory syncytial virus
- Meeting Date: December 2025
- Public Summary Document (PSD) July 2025 December 2025 PBAC Meeting - (PDF 1MB)
- Public Summary Document (PSD) July 2025 December 2025 PBAC Meeting - (Word 423KB)
Respiratory Syncytial Virus Vaccine – July 2025 – December 2025
Respiratory Syncytial Virus Vaccine; Powder and suspension for injection (0.5 mL); Arexvy®
Last updated
15 September 2026